Drug Search Results
Using advanced filters...
Advanced Search [+]

Elubrixin

Alternative Names: elubrixin, sb-656933, sb656933
Clinical Status: Inactive
Latest Update: 2018-03-14
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CXCR2 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Cystic Fibrosis|Colitis, Ulcerative

Phase 1: Chronic Obstructive Pulmonary Disease|Cystic Fibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

CF2110398

P1

Completed

Cystic Fibrosis

2008-12-01

2019-03-18

Treatments

CR2111256

P1

Completed

Chronic Obstructive Pulmonary Disease

2008-07-24

2019-03-18

Treatments

CR2100597

P1

Completed

Chronic Obstructive Pulmonary Disease

2008-07-22

2019-03-22

Treatments

CR2100609

P1

Completed

Chronic Obstructive Pulmonary Disease

2007-09-06

2019-03-21

Treatments

NCT00903201

P2

Completed

Cystic Fibrosis

2010-12-29

2019-03-18

Treatments

2010-018738-27

P2

Completed

Cystic Fibrosis

2010-12-29

2022-03-13

Treatments

CUC111342

P2

Terminated

Colitis, Ulcerative

2009-12-12

2019-03-18

Treatments

2007-005520-32

P2

Terminated

Colitis, Ulcerative

2009-10-01

2022-03-12

Treatments

Recent News Events

Date

Type

Title